Early life gut dysbiosis and inflammatory bowel diseases: Restoration and disease prevention

Research Objectives

Dr Eugene B. Chang and Dr Jun Miyoshi explore the impact of altered or dysbiotic early life gut microbiomes as risk factors for inflammatory bowel diseases and the importance of rebalancing the dysbiosis in early life to achieve proper immune development and lower risk for disease later in life.

Detail

Eugene B. Chang MD
Department of Medicine
900 E 57th Street
Knapp Center for Biomedical Discovery (Rm 9130)
University of Chicago
Chicago, IL 60637

Jun Miyoshi, M.D., Ph.D.
Associate Professor
Department of Gastroenterology and Hepatology
Kyorin University School of Medicine
6-20-2 Shinkawa, Mitaka-shi, Tokyo Japan 181-8611

Bio
Dr Chang is the Martin Boyer Distinguished Professor of Medicine, Director of the Microbiome Medicine Program, and physician-scientist at the University of Chicago; Dr Miyoshi is Associate Professor and physician-scientist at the Kyorin University (Tokyo). Both are experts in the study of host-gut microbiome interactions in health and disease.

Funding
NIDDK RC2DK122394-02; NIDDK R01DK47722, Gastrointestinal Research Foundation of Chicago; NIDDK P30 DK042086

Collaborators
Jun and Sawako Miyoshi (Kyorin University, Tokyo); Vanessa Leone (UWisconsin-Madison); Candace Cham (UCHicago); A. Murat Eren (UCHicago)

References


Personal Response

Can an imbalanced or damaged early life gut microbiome be restored and why is this important for the future outlook of a person’s health and disease?

The early life microbiome provides key signals and factors that are essential for proper development of host immunity, an educational process that takes place in the first year or two of life. Correction of imbalances in the early life gut microbiome arising from dietary, environmental, and pharmacological factors can potentially restore gut microbial and immune development and lower risk for complex immune disorders such as inflammatory bowel diseases. Development of reliable markers and indicators of gut microbial health or unhealth will lead to next generation of clinical tools for risk assessment, precision interventions, and monitoring the health of an individual.
Early life gut dysbiosis and inflammatory bowel diseases

Restoration and disease prevention

Perturbations of the early gut microbiome (dysbiosis) arising from antibiotic exposure, C-section, western diets, and formula feeding may affect later life risk for complex immune disorders like inflammatory bowel diseases (IBD). The research team led by Dr. Eugene B. Chang (University of Chicago) and Dr. Jun Miyoshi (Kyorin University) finds that key microbes essential to immune development are often missing in early life dysbiosis. Reintroduction of these microbes in early life (but not later in life) successfully restores development of the gut microbiome, immunity, and health. Their experimental findings highlight the importance of identifying early life dysbiosis and introducing timely interventions as part of future best practices.

Inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease are chronic but manageable conditions. In modern times, they have been increasing in incidence at an alarming rate. Numerous factors play a role in the development of these conditions, including the environment, genetics, gut microbes, and early life imbalances in the gut microbiome (called dysbiosis) resulting from exposure to antibiotics or to the impact of formula feeding, malnutrition, or overnutrition. As a consequence, 'health-essential' microorganisms and the gut environment or ecosystem that they naturally inhabit (commonly referred to as the 'microbiome' - from the ancient Greek 'mikros' [small] and 'bios' [life]) can be severely disturbed and have both short- or long-term health implications, e.g., increased risk of developing IBD (Miyoshi et al, 2021a; Gevers, et al, 2021). These implications have been highlighted by a promising area to start with might be PREDICTIVE MARKERS NITROGEN METABOLISM AS A PREDICTIVE MARKER. A diverse array of factors can cause perturbations in the gut microbiome.

The healthy development of the early life gut microbiome sets the stage for proper host immune development and lower risk for IBD. The Chicago research team found that the antibiotic-induced early life gut dysbiosis lacked many 'keystone' microbes that were essential to the development of host immunity. This in turn was associated with increases in severity and incidence of colitis in later life. These observations closely parallel clinically observed associations and were later confirmed by another group (Schüffeler, et al). Furthermore, they demonstrated that the engraftment of a vital missing keystone strain into the early life gut dysbiosis resulted in a significant decrease in the incidence and severity of colitis. In contrast, the engraftment of the same strain into the antibiotic-induced gut dysbiosis of adult mice did not have this protective effect (Miyoshi et al, 2021a). Thus, the intervention must be performed during a critical window in early life when the host immune system is still receptive to conditioning (Miyoshi et al, 2021a; Miyoshi et al, 2017). These findings underscore the importance of a judicious use of broad-spectrum antibiotics during late-term pregnancies or the neonatal period (Miyoshi et al, 2021a).

Studies of human subjects are still very limited and very difficult to conduct over the span of decades. Consequently, there are no reliable indicators to predict risk for IBD. In order to make significant advances in the field of human IBD, scientists still need to identify functional metrics which are more informative of potential impact of gut microbiomes to their host and may be useful for predicting future disease risk (Miyoshi et al, 2021b).

MICROBIOTA PATHWAYS OF NITROGEN METABOLISM AS PREDICTIVE MARKERS

A promising area to start with might be the nitrogen metabolism pathways. Within weeks after new offspring were born, Drs Miyoshi, Lee, Chang, and colleagues traced the differences between the functional (metagenomic) pathways of microbiota of mice that developed colitis later in life versus those that remained disease free. They found that bacterial nitrogen flux is associated with the incidence of overt colitis, where ammonia biosynthetic pathways were much more highly expressed in the mice with IBD than the ones without. The researchers opined that these types of markers can be useful predictors of risk for IBD in humans (Miyoshi et al, 2021b) in two ways. First, changes or imbalances in microbial metabolism and metabolites can set the stage whereby the host immune system is activated to cause disease. Second, the gut microbiome is highly sensitive to its environment and exhibits adaptive changes that can be detected as harbingers of clinical disease. In essence, the gut microbiome serves as the 'canary in the coal mine' where changes in its membership and function are early indicators of risk or development of diseases like IBD.

Changes in the gut microbiome can be early indicators of IBD risk.
Complex science made beautifully accessible

Partnership enquiries: simon@researchfeatures.com